Intravitreal Dexamethasone Implant for Postoperative Macular Oedema Secondary to Vitrectomy for Epiretinal Membrane and Retinal Detachment: A Systematic Review and Meta-Analysis.
Journal
Journal of ophthalmology
ISSN: 2090-004X
Titre abrégé: J Ophthalmol
Pays: United States
ID NLM: 101524199
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
12
2020
revised:
06
03
2021
accepted:
05
04
2021
entrez:
6
5
2021
pubmed:
7
5
2021
medline:
7
5
2021
Statut:
epublish
Résumé
To evaluate the efficacy of intravitreal dexamethasone implant (DEX) for the treatment of macular oedema secondary to vitrectomy for epiretinal membrane (ERM) and retinal detachment (RD) by conducting a systematic review with meta-analysis of published studies. Studies reporting clinical outcomes of DEX use for the treatment of macular oedema secondary to ERM and RD vitrectomy were searched on PubMed and Embase databases. The primary outcome was best-corrected visual acuity (BCVA) change between baseline and post-DEX treatment, reported as mean difference (MD) with 95% confidence interval (CI). Mean central macular thickness (CMT) change was assessed as a secondary outcome. Postimplant adverse events, including intraocular pressure rise and cataract development, were reported as well. Five uncontrolled studies, 1 nonrandomized controlled study, and 1 randomized controlled study were included, with a total of 5 cohorts and 3 cohorts in the ERM group and RD group, respectively. Considering the last available follow-up, a significant improvement in postimplant BCVA was found in the overall population, irrespective of the indication for vitrectomy (MD = -0.28, 95% CI = -0.37, -0.20; This meta-analysis showed that DEX yielded a significant improvement in visual and anatomical outcomes, even if limited by significant heterogeneity. Dexamethasone implant represents an effective treatment for postoperative macular oedema secondary to ERM and RD vitrectomy.
Identifiants
pubmed: 33953965
doi: 10.1155/2021/6627677
pmc: PMC8064798
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
6627677Informations de copyright
Copyright © 2021 Guglielmo Parisi et al.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Eye (Lond). 2020 Apr;34(4):683-689
pubmed: 31527762
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Eur J Ophthalmol. 2015 Jul 30;25(5):e98-e100
pubmed: 25790811
Ophthalmologica. 2012;227(2):61-7
pubmed: 21921587
Surv Ophthalmol. 2002 Aug;47 Suppl 1:S203-18
pubmed: 12204717
J Pharmacol Sci. 2018 Dec;138(4):219-232
pubmed: 30503676
Ophthalmology. 2016 Feb;123(2):316-323
pubmed: 26681390
Drug Des Devel Ther. 2017 Aug 16;11:2359-2372
pubmed: 28860707
ANZ J Surg. 2003 Sep;73(9):712-6
pubmed: 12956787
Br J Ophthalmol. 2017 Mar;101(3):333-341
pubmed: 27190126
Graefes Arch Clin Exp Ophthalmol. 2015 Jan;253(1):47-56
pubmed: 24859385
Eur J Ophthalmol. 2015 Nov-Dec;25(6):565-70
pubmed: 25907288
Retina. 2009 Sep;29(8):1119-27
pubmed: 19734764
Acta Ophthalmol. 2021 Feb;99(1):e74-e80
pubmed: 32588978
Invest Ophthalmol Vis Sci. 2011 Jan 05;52(1):249-55
pubmed: 20720227
J Ophthalmol. 2018 Dec 10;2018:5832186
pubmed: 30693103
Retina. 2011 May;31(5):915-23
pubmed: 21487341
Cutan Ocul Toxicol. 2020 Mar;39(1):25-30
pubmed: 31691630
Surv Ophthalmol. 2015 Mar-Apr;60(2):123-37
pubmed: 25438734
Ophthalmologica. 2019;242(1):16-21
pubmed: 30889589
Surv Ophthalmol. 2021 May-Jun;66(3):441-460
pubmed: 32918934
Ocul Immunol Inflamm. 2021 Jan 2;29(1):187-192
pubmed: 31577459
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
Acta Ophthalmol. 2020 Dec 16;:
pubmed: 33326183
Retina. 2014 Aug;34(8):1612-6
pubmed: 24752008
J Ophthalmol. 2020 Apr 28;2020:3946531
pubmed: 32411428
PLoS One. 2018 Jul 19;13(7):e0201010
pubmed: 30024983
Ophthalmology. 2009 Aug;116(8):1531-7
pubmed: 19501405
Retina. 2019 Nov;39(11):2107-2115
pubmed: 30161094
Retina. 2018 Jun;38(6):1084-1090
pubmed: 28622270
Ophthalmologica. 2017;237(4):232-237
pubmed: 28463851